2017
DOI: 10.2967/jnumed.116.177279
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Antiatherogenic Properties of Ezetimibe Using 3H-Labeled Low-Density-Lipoprotein Cholesterol and 99mTc-cAbVCAM1–5 SPECT in ApoE−/− Mice Fed the Paigen Diet

Abstract: The addition of ezetimibe, an intestinal cholesterol absorption inhibitor, to statin therapy has recently shown clinical benefits in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more than statin therapy alone. Here, we investigated the mechanisms by which inhibition of intestinal cholesterol absorption might contribute to the clinically observed reduction in cardiovascular events by evaluating its effect on inflammatory pl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 20 publications
(10 citation statements)
references
References 19 publications
0
9
0
Order By: Relevance
“…Otherwise, the specificity of dual-MPIO could be further increased in the future by replacing the two separate antibodies that target VCAM-1 and P-selectin with bispecific antibodies that simultaneously target both VCAM-1 and P-selectin [87]. In vivo: ApoE −/− on WD; In vivo: effect of statins on the atherosclerotic lesions in ApoE −/− on WD; In vivo: effect of ezetimibe on the atherosclerotic lesions in ApoE -/on Paigen Diet [111][112][113] Nuclear imaging Fluorine-18 Nanobody (cAbVCAM-1-5)…”
Section: Imaging Of Vcam-1mentioning
confidence: 99%
See 1 more Smart Citation
“…Otherwise, the specificity of dual-MPIO could be further increased in the future by replacing the two separate antibodies that target VCAM-1 and P-selectin with bispecific antibodies that simultaneously target both VCAM-1 and P-selectin [87]. In vivo: ApoE −/− on WD; In vivo: effect of statins on the atherosclerotic lesions in ApoE −/− on WD; In vivo: effect of ezetimibe on the atherosclerotic lesions in ApoE -/on Paigen Diet [111][112][113] Nuclear imaging Fluorine-18 Nanobody (cAbVCAM-1-5)…”
Section: Imaging Of Vcam-1mentioning
confidence: 99%
“…Therefore, Broisat et al generated the technetium-99m-labeled anti-VCAM-1 nanobody ([ 99m Tc]Tc-cAbVCAM-1-5) recognising mouse and human homologues that successfully detect atherosclerosis by SPECT/CT imaging [111]. [ 99m Tc]Tc-cAbVCAM-1-5 was also used to demonstrate the antiatherogenic effect of statins [112] and ezetimibe [113] in a mouse model of atherosclerosis. It is a specific, sensitive and reproducible tool for the non-invasive imaging of atherosclerosis and the evaluation of novel antiatherogenic agents, which requires clinical validation.…”
Section: Imaging Of Vcam-1mentioning
confidence: 99%
“…Thermal unfolding of A1 or C6 was therefore monitored by circular dichroism. A1, C6, and an irrelevant control sdAb were then radiolabeled with 99m Tc using the tricarbonyl method and the C-terminal hexahistidine-tag as previously described (19). The radiochemical purity of all 3 sdAbs was determined immediately after labeling and 6 h after labeling by radio-high-performance liquid chromatography (Shimadzu).…”
Section: Radiolabeling With 99m Tcmentioning
confidence: 99%
“…To assess the role of VCAM-1 in the metastatic phenotype of BC, nuclear imaging may represent a powerful tool. We recently developed a single domain antibody (sdAb)-based radiotracer targeting VCAM-1 called 99m Technetium-cAbVCAM1-5 ( 99m Tc-cAbVCAM1-5), which is ongoing clinical transfer for detection of inflamed atherosclerosis lesions [20,21]. The aim of the present study was to assess VCAM-1 expression using 99m Tc-cAbVCAM1-5 in subcutaneous and lung metastasis mice models of TNBC.…”
Section: Introductionmentioning
confidence: 99%